{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:45:41Z","timestamp":1790862341277,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.08.021","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T18:41:25Z","timestamp":1630176085000},"page":"364-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of risk-reducing salpingo-oophorectomy in BRCA1\u20132 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC)"],"prefix":"10.1016","volume":"163","author":[{"given":"Carlo","family":"Saccardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Spagnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bonaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Alessandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tognazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerigo","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Simone","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Noventa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.08.021_bb0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0020","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0040","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2010.0043","article-title":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian","volume":"8","author":"Daly","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0045","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2005.01.039","article-title":"Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations","volume":"97","author":"Casey","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/GRF.0000000000000316","article-title":"Management of Preinvasive Lesions","volume":"60","author":"Patrono","year":"2017","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0065","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2015.09.018","article-title":"Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review","volume":"139","author":"Patrono","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers","volume":"124","author":"Domchek","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2012.06.015","article-title":"Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls","volume":"127","author":"Mingels","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0090","series-title":"WHO Classification Tumors- Female Genital Tumors","article-title":"High-grade serous carcinoma of the fallopian tube","author":"Crum","year":"2002"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/gyno.1993.1223","article-title":"Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary","volume":"50","author":"Bloss","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cam4.2725","article-title":"The fallopian tube as origin of ovarian cancer: change of diagnostic and preventive strategies","volume":"9","author":"Kyo","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0120","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.1117135109","article-title":"High-grade serous ovarian cancer arises from fallopian tube in a mouse model","volume":"109","author":"Kim","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PGP.0b013e31822ea955","article-title":"Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies:a study of 300 consecutive cases","volume":"31","author":"Tang","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0130","first-page":"848","article-title":"Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clon.2018.03.036","article-title":"Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review","volume":"30","author":"Van der Hoeven","year":"2018","journal-title":"Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0140","first-page":"5241","article-title":"Risk-reducing Salpingo-Oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series","volume":"37","author":"Ricciardi","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0145","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12094-018-1865-9","article-title":"Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study","volume":"20","author":"Minig","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0150","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Riskreducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical\u2013pathological protocol","volume":"21","author":"Powell","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingooophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-019-0525-1","article-title":"Development of peritoneal carcinoma in women diagnosed with serous tubal intraepithelial carcinoma (STIC) following risk-reducing Salpingo-oophorectomy (RRSO)","volume":"25","author":"Stanciu","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0165","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14737140.2016.1247699","article-title":"Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management","volume":"16","author":"Weinberger","year":"2016","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following riskreducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","author":"Colombo","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.021_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1471-0528.2010.02768.x","article-title":"Utility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis","volume":"118","author":"Haldar","year":"2011","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2021.08.021_bb0190","first-page":"16","article-title":"The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review","volume":"1","author":"Blok","year":"2016","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2021.08.021_bb0195","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine Cancer after risk-reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:19Z","timestamp":1758772759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013196"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of risk-reducing salpingo-oophorectomy in BRCA1\u20132 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}